Endpoints News Feb 18, 2026 Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Endpoints News Feb 18, 2026 Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Endpoints News Feb 17, 2026 FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher